IL17A and gastroesophageal reflux disease: Combined with the core targets enriched in Th17 and IL-17 pathways, we selected TGF-β1, IL-1β, IL-8, IL-4, IL-10, and other inflammatory factors to monitor the effect of SHR on GERD.